PSMA PET for the Staging and Management of Hepatocellular Carcinoma
Recruiting now
Conditions studied: Hepatocellular Carcinoma (HCC)
In brief
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.
Key facts
- Study ID
- NCT07019844
- Run by
- VA Office of Research and Development
- People needed
- 90
- Starts
- 2024-09-19
- Expected to finish
- 2028-09-30
- Last updated by the study team
- 2026-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients age >18 years from the VA medical system
- Treatment-naïve patients with HCC with BCLC B or C disease
You may not qualify if…
- Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging
- Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years
Where it is running
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California, United States (enrolling)
- Miami VA Healthcare System, Miami, FL — Miami, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.